Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Decker

Pulmonary Disease Adrian, MI Doctor of Osteopathy

NPI 1942205208 CMS profile 314970

777 Kimole Lane Suite 100, Adrian, MI 49221

Open in the dashboard

General payments

$10,136

578 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Decker of Adrian, MI is reported in the CMS Open Payments database as having received $10,136 across 578 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,580 99
2024 General $1,516 75
2023 General $1,535 92
2022 General $1,694 85
2021 General $1,285 78
2020 General $1,340 76
2019 General $1,185 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Decker
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to William Decker were reported at $1,580. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year William Decker Pulmonary Disease median Middle half National median
2019 $1,185 $377 $109–$1,340 $163
2020 $1,340 $230 $56–$907 $114
2021 $1,285 $269 $68–$1,072 $132
2022 $1,694 $390 $100–$1,457 $149
2023 $1,535 $419 $114–$1,659 $160
2024 $1,516 $476 $123–$1,818 $164
2025 $1,580 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,824 103 payments
  2. Mylan Specialty L.P. $1,282 68 payments
  3. Regeneron Healthcare Solutions, Inc. $1,085 62 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,081 65 payments
  5. GlaxoSmithKline, LLC. $900 58 payments
  6. Genzyme Corporation $581 35 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $305 16 payments
  8. Insmed, Inc. $300 27 payments
  9. CSL Behring $284 15 payments
  10. Janssen Pharmaceuticals, Inc $232 13 payments
  11. Other $2,262 116 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,938 572 payments
  2. Education $198 6 payments
Products named General payments · program years 2019–2025
  1. YUPELRI Anticholinergics, Inhaled $1,020 50 payments
  2. DUPIXENT Inflammation And Immunology $946 54 payments
  3. DUPIXENT Immunology $650 35 payments
  4. TRELEGY ELLIPTA $532 36 payments
  5. OFEV $508 31 payments
  6. SPIRIVA RESPIMAT $489 31 payments
  7. SYMBICORT $470 27 payments
  8. FASENRA $450 22 payments
  9. BREZTRI $407 23 payments
  10. Yupelri Respiratory and Allergy $353 22 payments
  11. Other $6,158 350 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

5,500

Median for Pulmonary Disease: 936

Drug cost

$1,760,959

Median for Pulmonary Disease: $487,987

Branded share of claims

54.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 1,148 $915,334
Trikafta Elexacaftor/Tezacaftor/Ivacaft Brand 12 $326,834
Eliquis Apixaban Brand 65 $63,723
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 91 $58,519
Dupixent Pen Dupilumab Brand 15 $55,849
Dupixent Syringe Dupilumab Brand 11 $41,103
Albuterol Sulfate Hfa Albuterol Sulfate Brand 674 $30,107
Spiriva Respimat Tiotropium Bromide Brand 32 $29,666
Symbicort Budesonide/Formoterol Fumarate Brand 86 $29,470
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 77 $25,374

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$134,771

Medicare's payments for the services billed

Medicare patients

516

Average age 73

Services billed

1,738

280 women, 236 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 58%
Arthritis 50%
Heart failure 39%
Diabetes 37%
Ischemic heart disease 34%
Chronic kidney disease 31%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $239
  • GENZYME CORPORATION $18
$257 26 —
YUPELRI
  • Mylan Specialty L.P. $170
$170 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $161
$161 1,148 —
AREXVY
  • GlaxoSmithKline, LLC. $121
$121 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

578 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record